Sodium Bicarbonate Injection

1) Treat metabolic acidosis. This product increases the concentration of carbonate in plasma, neutralizes hydrogen ions, and corrects acidosis. (2) Alkalize urine. As the concentration of carbonate in urine increases, the pH value increases, making it difficult for uric acid, sulfonamide drugs, and hemoglobin to form crystals or aggregate in urine. (3) Antacid. Oral administration can quickly neutralize or buffer gastric acid without directly affecting gastric acid secretion. Therefore, the pH in the stomach increases rapidly, alleviating the symptoms caused by high gastric acid.

The main ingredients of this product and its chemical name: sodium bicarbonate. Structural formula: NaHCO3 Molecular formula: NaHCO3 Molecular weight: 84.01

This product is a colorless clear liquid.

(1) Treatment of chemical acidosis. For the treatment of mild to moderate chemical acidosis, oral administration is preferred. For severe chemical acidosis, intravenous drip should be used, such as in severe kidney disease, circulatory failure, cardiopulmonary resuscitation, extracorporeal circulation, severe primary lactic acidosis, diabetic ketoacidosis, etc. (2) Alkalization of urine. Used for the prevention of uric acid kidney stones, reducing the renal toxicity of sulfonamide drugs, and acute hemolysis to prevent hemoglobin deposition in the renal tubules. (3) As an antacid, it treats symptoms caused by excessive gastric acid. (4) Intravenous drip has a non-specific therapeutic effect on certain drug poisonings, such as poisoning by barbiturates, salicylates, and methanol. However, this product is contraindicated for gastric lavage in case of ingestion of strong acid poisoning, because this product reacts with strong acid to produce a large amount of carbon dioxide, which can lead to acute gastric dilatation or even gastric rupture.

Metabolic acidosis, intravenous drip, the required dose is calculated as follows: alkali supplement amount (mmol) = (-2.3-actually measured BE value) x 0.25 x body weight (kg), or alkali supplement amount (mmol) = [normal CO2CP-actually measured CO2CP (mmol)] x 0.25 x body weight (kg). Unless the body loses bicarbonate, generally give 1/3 to 1/2 of the calculated dose first, and drip it in 4 to 8 hours. During cardiopulmonary resuscitation, the first dose is 1mmol/kg, and the dose is adjusted according to the results of blood gas analysis (each 1g of sodium bicarbonate is equivalent to 12mmol bicarbonate). The following issues should also be noted for intravenous medication: ① The concentration range of intravenous application is 1.5% (isotonic) to 8.4%; ② Start with a small dose, and determine the additional dose based on the changes in blood pH and bicarbonate concentration; ③ Short-term large-scale intravenous infusion can cause severe alkalosis, hypokalemia, and hypocalcemia. When the dosage exceeds 10ml of hypertonic solution per minute, it can cause hypernatremia, decreased cerebrospinal fluid pressure and even intracranial hemorrhage, which is more likely to occur in newborns and children under 2 years old. Therefore, when infusing a 5% solution, the speed cannot exceed 8mmol of sodium per minute. However, during cardiopulmonary resuscitation, due to the presence of fatal acidosis, rapid intravenous infusion should be given. Alkalinize urine, adults: oral administration of 4g for the first time, and 1-2g every 4 hours thereafter. Intravenous drip, 2-5mmol/kg, the drip should be completed within 4-8 hours. Children: Oral, 1-10mmol/kg per day based on body weight.

(1) When a large amount of injection is given, arrhythmia, muscle cramps, pain, abnormal fatigue and weakness may occur, mainly due to hypokalemia caused by metabolic alkalosis. (2) When the dose is too large or there is renal insufficiency, edema, mental symptoms, muscle pain or convulsions, slow breathing, bad taste in the mouth, abnormal fatigue and weakness may occur. Mainly caused by metabolic alkalosis. (3) Long-term use may cause frequent urination, urgent urination, persistent headache, loss of appetite, nausea and vomiting, abnormal fatigue and weakness, etc.

(1) Metabolic or respiratory alkalosis; (2) Metabolic alkalosis is very likely to occur due to vomiting or continuous gastrointestinal negative pressure suction leading to a large amount of chloride loss; (3) In the case of hypocalcemia, alkalosis caused by this product can aggravate the symptoms of hypocalcemia. (4) This product is contraindicated for gastric lavage in the case of ingestion of strong acid poisoning, because this product reacts with strong acid to produce a large amount of carbon dioxide, causing acute gastric dilatation or even gastric rupture.

Precautions for children: For the treatment of acidosis, refer to the adult dose. During cardiopulmonary resuscitation, the first intravenous injection is 1mmol/kg of body weight, and the dosage is adjusted according to the results of blood gas analysis. Precautions for pregnancy and lactation: 1. Long-term or large-scale use can cause metabolic alkalosis, and excessive sodium load can cause edema, etc. Pregnant women should use it with caution. 2. This product can be secreted through breast milk, but there is no relevant information on its effects on infants. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

(1) When used in combination with adrenocortical hormones (especially those with strong mineralocorticoid effects), adrenocorticotropic hormone, and androgens, hypernatremia and edema are likely to occur. (2) When used in combination with amphetamine and quinidine, the renal excretion of the latter two is reduced, which is prone to toxic effects. (3) When used in combination with anticoagulants such as warfarin and M cholinesterase drugs, the absorption of the latter is reduced. (4) When used in combination with calcium-containing drugs, milk and dairy products, milk-alkali syndrome may occur. (5) When used in combination with H2 receptor antagonists such as cimetidine and ranitidine, the absorption of the latter is reduced. (6) When used in combination with potassium-excreting diuretics, the risk of hypochloremic alkalosis is increased. (7) This product can alkalinize urine and affect the renal excretion of ephedrine. Therefore, the dose of ephedrine should be reduced when used in combination. (8) The increase in sodium load increases the renal excretion of lithium. Therefore, when used in combination with lithium preparations, the dosage of lithium preparations should be adjusted as appropriate. (9) Alkalinizing urine can inhibit the conversion of methenamine into formaldehyde, thereby inhibiting the latter's therapeutic effect, so the two drugs are not recommended to be used together. (10) This product can increase the excretion of salicylic acid preparations by the kidneys by alkalinizing urine.

Keep tightly closed.

10ml:0.5g

Yangzhou Zhongbao Pharmaceutical Co., Ltd.

• Founded in:

  1991-11-15

• Address:

  No. 91, Baoying Avenue, New District, Economic Development Zone, Baoying County, Yangzhou City, Jiangsu Province

• Tax NO.:

  91321000608709261R

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view